Seeking Alpha

Jeremy Richards'  Instablog

Jeremy Richards
Send Message
Jeremy Richards is the Manager/Director of a private wealth fund. He has twenty years investment expertise. He left Wall Street and is much happier on Main Street.
  • Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna 7 comments
    Mar 6, 2012 10:59 PM | about stocks: KERX, AEZS
    I write in response to Mr. Feuerstein's uninformed, inflammatory and accusatory comments which are completely without merit. It is rather sad that the street.com allows such publications by "tabloid" journalists. Firstly, I run "a" Private Fund, not the California LLC Mr.Feuerstein mentions. It is "Private" and due to moral and professional considerations, I will not discuss the specific investors and/or funds in the fund. Secondly, Mr. Feuerstein challenges that the MDs in my Keryx (KERX) and AEterna-Zentaris (AEZS) article are not verifiable. Had Mr. Feuerstein thoroughly read and comprehended my previous articles that he mentioned, he would have seen that a significant amount of Dr. Wurlitzer's background in my November 14, 2011 article which actually contains his name within the title. Finally, Mr. Feuerstein inaccurately alleges that stockholder names are published on Bloomberg. Mr.Feuerstein may be living in the archaic days when paper stock certificates were registered and held. In today's modern world, shares are traded electronically and are typically held in "street name" meaning they are held in the name of the brokerage house. Further, for a brokerage to disclose an individual's name and holdings to Bloomberg would be a violation of the Gramm-Leach-Bliley (GLB) act. SEC regulations require the investor (not the brokerage) disclosure when 5% or more is held. If Mr. Feuerstein does the math, an investor would need to hold over 3 times the quoted levels to meet the threshold required.

    I sincerely hope that Mr. Feuerstein can focus on true market issues and focus on facts rather than propagating false and misleading information.

    Before investors take Mr. Feuerstein seriously I would highly recommend taking a look at the following site (exposeadam.com)

    The website is devoted to providing a forum to rebut and correct the numerous one sided articles written by Adam Feuerstein on behalf of the Street.com. Adam Feuerstein has been writing for the Street.com since 2001 and is marketed as their Senior Columnist although he has never attended journalism school nor does he have any formal education in Journalism. In fact, he has NO formal science background either (he was a political science major at Emory University) and thus his credibility and objectivity as a biotech journalist must be questioned. He has been sued by biotech companies for his one sided attacks. Additionally, his inaccurate reporting has even led to patient safety issues as outlined in this article about Oculus Innovative Sciences. There have been numerous articles written about his one sided tactics and his questionable timing and release of misleading headlines that can be found here. Under the guise of being a biotech journalist, Adam frequently writes misleading headlines and articles that are widely disseminated via the Street.com's media network.

    Disclosure: I am long KERX, AEZS.

    Stocks: KERX, AEZS
Back To Jeremy Richards' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (7)
Track new comments
  • This should make an interesting day,wednesday.
    7 Mar 2012, 04:30 AM Reply Like
  • well it didnt work we got slaughtered again
    7 Mar 2012, 09:25 PM Reply Like
  • AG comment: OK this makes sense, the trial is to show that patients live longer through Perifosine treatment, although two months is hardly much of a lifespan improvement........Ric... is saying that 6.5 months is too long a time to assume the patients will live under the CAP treatment. I don't see how this is a positive comment for Perifosine, it is a neutral comment.

     

    If they conservatively estimate 6.5 months when in reality it is .75 months shorter, that boosts the survival to about 3 additional months. So, if we now look @ this in terms of percentages, Perifosine increases life expectancy 60%. that is NOT a statistically insignificant number. It does not matter to the FDA if you think it is a lifespan improvement for APPROVAL it requires an advantage over an existing drug, which if it is 3 months - then 60% is a huge increase.
    8 Mar 2012, 02:22 AM Reply Like
  • Seems no one heard Jeremy Richards responce. Wonder why,could it be Adam Feuerstein has a special interest? Adam Feuestein has been right many times but to be fair I believe Jeremy Richards responce should be published in main stream media ,which it has not been.What would it do for the stock price? Most likely right back up again.
    8 Mar 2012, 04:02 AM Reply Like
  • Your facts have not been correct as well. You said in a previous article that the phase III trial had completed enrollment in march of 2011, when in fact just over half had been enrolled. Enrollment was not completed until July of 2011.
    8 Mar 2012, 09:09 AM Reply Like
  • I second the scum!!!!!
    9 Mar 2012, 08:29 PM Reply Like
  • The argument seems a bit moot now, doesn't it Jeremy? Jeremy? Jeremey? You out there? Gee, what a shock, complete silence from Mr. Richards - other than changing the Twitter account and deleteing several old posts re: Kerx.
    10 Apr 2012, 11:13 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • (CPST) stoploss at $1.10.
    Feb 28, 2012
  • (ARNA) I like the upside potential here. I will have a research article out this weekend. $5 to $8 potential upside.
    Jan 27, 2012
  • (CPST) I like the company. CPST has very good potential for a major short squeeze. limited downside risk and good upside reward. Breakout.
    Jan 24, 2012
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.